FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2174-2176 November 13, 2008 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lohrmann, J. Related Article by Eriksson, B. I. Related Article by Lassen, M. R. PubMed Citation

To the Editor: The studies by Eriksson et al. and Lassen et al. (June 26 issue)^1,2 show the superiority of oral rivaroxaban over a fixed dose of enoxaparin for thromboprophylaxis. In both studies, there was a wide range in the body weights of the patients, with the weights at the low and high ends of the range differing by a factor of more than three. Was there any difference in effectiveness or safety as a function of body weight?

Edward P. Schuman, M.D.
Holy Redeemer Hospital and Medical Center
Meadowbrook, PA 19046

1. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775. [Free Full Text]
2. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786. [Free Full Text]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.